A clinical trial to study the effects of two drugs, Vasa Ghanavati & Vasa Avaleha in patients of Tamaka Shwasa(Bronchial Asthma)

A Comparative efficacy of Vasa Ghanavati and Vasa Avaleha in the Management of Tamaka Shwasa(Bronchial Asthma) - VG & VA (VG: Vasa Ghanavati & VA: Vasa Avaleha)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/02/007754

Enrollment

Registered

2017-02-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patient having classical symptomatology of Tamaka Shwasa(Bronchial Asthma), Special proforma prepared for inclusion of sign & symptoms of the disease as per Ayurveda and modern science.

Interventions

Intervention1: VG vasaghanvati VA vasa avaleha: VG vasaganvati 300mg 2 tablet BD for 28 days VA vasa avaleha 10gm BD for 28 days Intervention2: VA vasa avaleha: VA vasa avaleha 10gm BD for 28 days C

Eligibility

Inclusion criteria

Inclusion criteria: patient having classical symptomatology of Tamaka Shwasa(Bronchial Asthma), Special proforma prepared for inclusion of sign & symptoms of the disease as per Ayurveda and modern science

Exclusion criteria

Exclusion criteria: Patient with associated disease like Heart disease, Tuberculosis, Hypertension, Diabetes Mellitus, Cancer, HIV, Parenchymal Lung disease- Lung Collapse, Cardiac asthma, Pleural Effusion, Pneumothorax, Pregnant women, Lacting mother and any other chronic severe illness

Design outcomes

Primary

Measure	Time frame
pharmaceutical study of VG and VA complited.Timepoint: 3 months	—

Secondary

Measure	Time frame
Not yetTimepoint: Not yet	—

Countries

India

Contacts

Public ContactDr Upendra U Zala

J.S.Ayurveda college, Nadiad Gujarat

barjodhansraj1237@gmail.com9978241518

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026